[1] Rouatbi M, Amairia S, Amdouni Y, Boussaadoun MA, Ayadi O, Al-Hosary AAT, et al. Toxoplasma gondii infection and toxoplasmosis in North Africa: a review. Parasite, 2019; 26:6. doi: 10.1051/parasite/2019006.
[2] McFarland, M, Bartlett, M, Davis, P. Toxoplasmic Encephalitis. Edition: 1, Chapter: 1, Publisher: Avid Science, Editors: Avid Science. Encephalitis, 2016;pp: 2-52.
[3] Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.[EB/OL]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf [accessed May 16, 2020].
[4] Luma HN, Tchaleu BC, Mapoure YN, Temfack E, Doualla MS, Halle MP, et al. Toxoplasma encephalitis in HIV/AIDS patients admitted to the Douala general hospital between 2004 and 2009: a cross sectional study. BMC Res Notes, 2013;6:146. doi: 10.1186/1756-0500-6-146.
[5] Libório AB, Silva GB Jr, Silva CG, Filho FL, Neto AS, Okoba W, et al. Hyponatremia, acute kidney injury, and mortality in HIV-related toxoplasmic encephalitis. Braz J Infect Dis, 2012;16(6):558-563. doi: 10.1016/j.bjid.2012.08.015.
[6] Sonneville R, Schmidt M, Messika J, Hssain AA, Daniel da S, Klein IF, et al. Neurologic outcomes and adjunctive steroids in HIV patients with severe cerebral toxoplasmosis. Neurology, 2012;79(17):1762-1766. doi: 10.1212/WNL.0b013e3182704040.
[7] The National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, [EB/OL].(2019/6/26)[2020/5/16] https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxoplasma-gondii-encephalitis
[8] Vidal JE, Hernandez AV, de Oliveira AC, Dauar RF, Barbosa Jr SP, Focaccia R, et al. Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS, 2005;19(10):626-634. doi: 10.1089/apc.2005.19.626.
[9] Eapen BC, Georgekutty J, Subbarao B, Bavishi S, Cifu DX. Disorders of Consciousness. Phys Med Rehabil Clin N Am, 2017;28(2):245-258. doi: 10.1016/j.pmr.2016.12.003.
[10] Wang ZD, Wang SC, Liu HH, Ma HY, Li ZY, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis. Lancet HIV, 2017;4(4):e177-e188. doi: 10.1016/S2352-3018(17)30005-X.
[11] Landrith TA, Harris TH, Wilson EH. Characteristics and critical function of CD8+ T cells in the Toxoplasma-infected brain. Semin Immunopathol, 2015;37(3):261-270. doi: 10.1007/s00281-015-0487-3.
[12] Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect, 2007;13(5):510-515. doi: 10.1111/j.1469-0691.2007.01683.x.
[13] Augustinack JC, van der Kouwe AJ, Salat DH, Benner T, Stevens AA, Annese J, et al, H.M.'s contributions to neuroscience: a review and autopsy studies. Hippocampus, 2014;24(11):1267-1286. doi: 10.1002/hipo.22354.